Publicaciones en colaboración con investigadores/as de Hospital Universitario Príncipe de Asturias (26)

2024

  1. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  2. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

2023

  1. Myocardial revascularization failure among patients requiring cardiac catheterization and secondary revascularization in contemporary clinical practice: Results of the REVASEC multicenter registry

    Catheterization and Cardiovascular Interventions, Vol. 102, Núm. 4, pp. 608-619

2022

  1. Design and Rationale for a Real-World Prospective, Multicenter Registry of Myocardial Revascularization Failure and Secondary Revascularization: The REVASEC Study

    Cardiovascular Revascularization Medicine, Vol. 40, pp. 50-56

2020

  1. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

    Experimental Hematology and Oncology

2019

  1. Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry

    Rheumatology International, Vol. 39, Núm. 3, pp. 509-515

  2. Objectives and methodology of BIOBADASER phase III

    Reumatologia Clinica, Vol. 15, Núm. 4, pp. 229-236

2018

  1. A multicentre randomized pilot trial on the effectiveness of different levels of cooling in comatose survivors of out-of-hospital cardiac arrest: the FROST-I trial

    Intensive Care Medicine, Vol. 44, Núm. 11, pp. 1807-1815

  2. Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting: Protocol for a phase IV, single-arm, open-label trial

    BMJ Open, Vol. 8, Núm. 10

2017

  1. Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications

    Cytometry Part B - Clinical Cytometry, Vol. 92, Núm. 5, pp. 361-370

  2. Diagnóstico y tratamiento de la eosinofilia importada en viajeros e inmigrantes: Recomendaciones de la Sociedad Española de Medicina Tropical y Salud Internacional (SEMTSI)

    Revista Espanola de Quimioterapia, Vol. 30, Núm. 1, pp. 62-78

2016

  1. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method

    Annals of Hematology, Vol. 95, Núm. 5, pp. 719-732

  2. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

2014

  1. Hairy cell leukemia treated initially with purine analogs: A retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)

    Leukemia and Lymphoma, Vol. 55, Núm. 5, pp. 1007-1012

2012

  1. Chronic lymphocytic leukaemia with 17p deletion: A retrospective analysis of prognostic factors and therapy results

    British Journal of Haematology, Vol. 157, Núm. 1, pp. 67-74

  2. Response to imatinib mesylate in patients with hypereosinophilic syndrome

    International Journal of Hematology, Vol. 96, Núm. 3, pp. 320-326

2011

  1. Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: Toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03)

    Leukemia and Lymphoma, Vol. 52, Núm. 3, pp. 409-416

2010

  1. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms

    Journal of Allergy and Clinical Immunology, Vol. 125, Núm. 6

  2. Targeted genomic disruption of H-ras induces hypotension through a NO-cGMP-PKG pathway-dependent mechanism

    Hypertension, Vol. 56, Núm. 3, pp. 484-489

2009

  1. Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide

    Leukemia and Lymphoma, Vol. 50, Núm. 8, pp. 1283-1289